Fangzhou Tops China’s App Store Chart for Healthcare Apps
GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in the June 2025 China AppStore Healthcare TOP100 Free APP Rankings with its Fangzhou Online Pharmacy App, according to a report by the leading digital economy media outlet...
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
BOSTON, July 3, 2025 /PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment of MaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer. The move comes as MOTE accelerates development of its MOBILIZE platform, a modular LNP technology designed for extrahepatic delivery of circular RNA (circRNA) and other complex...
Esaote presents at ECVS 2025 the new generation of veterinary MRI, Vet -MR Grande ELITE
GENOA, Italy and ANTWERP, Belgium, July 3, 2025 /PRNewswire/ -- Esaote, a leading company in the field of medical diagnostic imaging, presents the new Vet -MR Grande ELITE, the next generation of veterinary MRI at the ECVS 2025, the Annual scientific meeting of European College of Veterinary Surgeon in Antwerp, Belgium held...
Akeso’s First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in ‘IO+ADC’ 2.0 Strategy
HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispecific ADC to enter clinical trials. AK146D1 has recently received approval from the U.S....
Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies. SAN ANTONIO, July 3, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Novotech has been awarded the 2025 Global Company of the Year Award in the biotech contract research...
Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningful benefits to patients SHANGHAI, July 3, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel...
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel Provides a clear pathway for...
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small molecule oral GLP-1 receptor agonist ASC30. - ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment in a U.S. Phase Ib study. - Topline data from ASC30...
Global Excel Acquires First Assistance to Strengthen Assistance Services and Expand in the Asia-Pacific Market
SHERBROOKE QC, July 3, 2025 /PRNewswire/ -- Global Excel Management Inc. (Global Excel) is pleased to announce the strategic acquisition of First Assistance New Zealand Limited (First Assistance) and its subsidiary First Assistance Australia Pty Ltd, leading businesses specializing in digital assistance services. This deal marks Global Excel's commitment to expanding its footprint in the travel assistance and...
SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response
SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different subtypes—potentially transforming how clinicians monitor treatment response. Study Highlights Innovative Approach: The SeekInClarity test integrates genomic, epigenetic, and proteomic signals from blood samples to calculate...
